retatrutide treatment duration clinical trials New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats When will Retatrutide be available

The most common adverse events were gastrointestinal in nature and consistent with other incretin-based drugs

A new study published in JAMA Internal Medicine examines the safety of glucagon-like peptide 1 (GLP-1) receptor agonists, along with other second-line medications used in managing diabetes in early pregnancy

Recovery What the timeline really looks like

The New England Journal of Medicine, 393(11), 10771087

Retatrutide is designed to activate GLP-1, GIP, and glucagon receptors (triple agonist), and researchers study how that impacts metabolic endpoints in clinical trials

Whether you need immediate medical support for severe dehydration, advanced diagnostic testing, or long-term management of chronic digestive issues, our specialists deliver the highest standard of compassionate, expert medical care you deserve